REGENXBIO Inc.

NASDAQ: RGNX · Real-Time Price · USD
9.04
-0.02 (-0.22%)
At close: Aug 15, 2025, 10:04 AM

REGENXBIO Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
83.33M 90.24M 112.72M 470.35M
Cost of Revenue
33.57M 37.21M 54.55M 51.83M
Gross Profit
49.76M 53.03M 58.18M 418.51M
Operating Income
-233.35M -268.13M -262.88M 159.98M
Interest Income
174K 25K 342K 719K
Pretax Income
-227.1M -263.65M -280.4M 141.25M
Net Income
-227.1M -263.49M -280.32M 127.84M
Selling & General & Admin
76.62M 88.49M 85.28M 79.33M
Research & Development
208.52M 232.27M 242.45M 181.44M
Other Expenses
-2.03M 397K -6.68M -2.24M
Operating Expenses
285.14M 321.16M 321.06M 258.53M
Interest Expense
12.66M 6.86M 23.25M 26.28M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
318.71M 358.37M 375.6M 310.37M
Income Tax Expense
n/a -152K -84K 13.41M
Shares Outstanding (Basic)
49.51M 43.73M 43.15M 42.44M
Shares Outstanding (Diluted)
49.51M 43.73M 43.15M 43.91M
EPS (Basic)
-4.59 -6.02 -6.5 3.01
EPS (Diluted)
-4.59 -6.02 -6.5 2.91
EBITDA
-198.23M -239.46M -244.24M 169.54M
EBIT
-214.44M -256.78M -257.15M 159.98M
Depreciation & Amortization
16.21M 17.32M 12.91M 9.56M